β-Catenin nuclear localization positively feeds back on EGF/EGFR-attenuated AJAP1 expression in breast cancer

Abstract Background Adherent junction associated protein 1 (AJAP1), a typical molecule of adherent junctions, has been found to be a tumor suppressor in many cancer types. Aberrant activation of β-catenin has been demonstrated to be associated with malignant biological properties of tumors including...

Full description

Bibliographic Details
Main Authors: Cong Xu, Fang Liu, Guomin Xiang, Lu Cao, Shuling Wang, Jing Liu, Qingxiang Meng, Danni Xu, Shuhua Lv, Jiao Jiao, Yun Niu
Format: Article
Language:English
Published: BMC 2019-06-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
EGF
Online Access:http://link.springer.com/article/10.1186/s13046-019-1252-6
id doaj-399d3cb3d3934303a7d0e19cc779e591
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Cong Xu
Fang Liu
Guomin Xiang
Lu Cao
Shuling Wang
Jing Liu
Qingxiang Meng
Danni Xu
Shuhua Lv
Jiao Jiao
Yun Niu
spellingShingle Cong Xu
Fang Liu
Guomin Xiang
Lu Cao
Shuling Wang
Jing Liu
Qingxiang Meng
Danni Xu
Shuhua Lv
Jiao Jiao
Yun Niu
β-Catenin nuclear localization positively feeds back on EGF/EGFR-attenuated AJAP1 expression in breast cancer
Journal of Experimental & Clinical Cancer Research
AJAP1
β-Catenin
Nuclear location
EGF
EGFR
Tumor progression
author_facet Cong Xu
Fang Liu
Guomin Xiang
Lu Cao
Shuling Wang
Jing Liu
Qingxiang Meng
Danni Xu
Shuhua Lv
Jiao Jiao
Yun Niu
author_sort Cong Xu
title β-Catenin nuclear localization positively feeds back on EGF/EGFR-attenuated AJAP1 expression in breast cancer
title_short β-Catenin nuclear localization positively feeds back on EGF/EGFR-attenuated AJAP1 expression in breast cancer
title_full β-Catenin nuclear localization positively feeds back on EGF/EGFR-attenuated AJAP1 expression in breast cancer
title_fullStr β-Catenin nuclear localization positively feeds back on EGF/EGFR-attenuated AJAP1 expression in breast cancer
title_full_unstemmed β-Catenin nuclear localization positively feeds back on EGF/EGFR-attenuated AJAP1 expression in breast cancer
title_sort β-catenin nuclear localization positively feeds back on egf/egfr-attenuated ajap1 expression in breast cancer
publisher BMC
series Journal of Experimental & Clinical Cancer Research
issn 1756-9966
publishDate 2019-06-01
description Abstract Background Adherent junction associated protein 1 (AJAP1), a typical molecule of adherent junctions, has been found to be a tumor suppressor in many cancer types. Aberrant activation of β-catenin has been demonstrated to be associated with malignant biological properties of tumors including breast cancer. This study aimed to investigate the function and mechanism of AJAP1-mediated β-catenin activity of breast cancer lines in vitro and in breast cancer patients. Methods AJAP1 and β-catenin expressions in breast cancer tissues and cell lines were detected by immunohistochemistry, western blotting and qRT-PCR. The EGF/EGFR axis-mediated AJAP1 attenuated β-catenin nuclear location was measured by western blotting, immunofluorescence assay, co-immunoprecipitation, luciferase assay and ubiquitination assays. Furthermore, the function of AJAP1 and β-catenin regulated breast cancer progression was explored both in vivo and in vitro. Results It was found that AJAP1 had a high negative correlation with β-catenin nuclear expression and was a novel tumor suppressor in breast cancer. AJAP1 loss can mediate β-catenin accumulated in cytoplasm and then transferred it to the nucleus, activating β-catenin transcriptional activity and downstream genes. Additionally, β-catenin can reverse the invasion, proliferation ability and tumorigenicity of the depletion of AJAP1 caused both in vivo and in vitro. Besides, EGF/EGFR also involved in the process of AJAP1-depiction induced β-catenin transactivation to the nucleus. More importantly, EGFR depletion/AJAP1 knocked down promoted the progression of breast cancer by regulating the activity of β-catenin nuclear transactivation. Conclusion This study demonstrated that AJAP1 acted as a putative tumor suppressor while β-catenin nuclear localization positively fed back on EGF/EGFR-attenuated AJAP1 expression in breast cancer, which might be beneficial to develop new therapeutic targets for decreasing nuclear β-catenin-mediated malignancy in breast cancer.
topic AJAP1
β-Catenin
Nuclear location
EGF
EGFR
Tumor progression
url http://link.springer.com/article/10.1186/s13046-019-1252-6
work_keys_str_mv AT congxu bcateninnuclearlocalizationpositivelyfeedsbackonegfegfrattenuatedajap1expressioninbreastcancer
AT fangliu bcateninnuclearlocalizationpositivelyfeedsbackonegfegfrattenuatedajap1expressioninbreastcancer
AT guominxiang bcateninnuclearlocalizationpositivelyfeedsbackonegfegfrattenuatedajap1expressioninbreastcancer
AT lucao bcateninnuclearlocalizationpositivelyfeedsbackonegfegfrattenuatedajap1expressioninbreastcancer
AT shulingwang bcateninnuclearlocalizationpositivelyfeedsbackonegfegfrattenuatedajap1expressioninbreastcancer
AT jingliu bcateninnuclearlocalizationpositivelyfeedsbackonegfegfrattenuatedajap1expressioninbreastcancer
AT qingxiangmeng bcateninnuclearlocalizationpositivelyfeedsbackonegfegfrattenuatedajap1expressioninbreastcancer
AT dannixu bcateninnuclearlocalizationpositivelyfeedsbackonegfegfrattenuatedajap1expressioninbreastcancer
AT shuhualv bcateninnuclearlocalizationpositivelyfeedsbackonegfegfrattenuatedajap1expressioninbreastcancer
AT jiaojiao bcateninnuclearlocalizationpositivelyfeedsbackonegfegfrattenuatedajap1expressioninbreastcancer
AT yunniu bcateninnuclearlocalizationpositivelyfeedsbackonegfegfrattenuatedajap1expressioninbreastcancer
_version_ 1724746364400697344
spelling doaj-399d3cb3d3934303a7d0e19cc779e5912020-11-25T02:48:50ZengBMCJournal of Experimental & Clinical Cancer Research1756-99662019-06-0138111610.1186/s13046-019-1252-6β-Catenin nuclear localization positively feeds back on EGF/EGFR-attenuated AJAP1 expression in breast cancerCong Xu0Fang Liu1Guomin Xiang2Lu Cao3Shuling Wang4Jing Liu5Qingxiang Meng6Danni Xu7Shuhua Lv8Jiao Jiao9Yun Niu10Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for CancerTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for CancerTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for CancerTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for CancerTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for CancerTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for CancerTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for CancerTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for CancerDepartment of Pathology, Tianjin Union Medical Center, Tianjin People’s HospitalTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for CancerTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for CancerAbstract Background Adherent junction associated protein 1 (AJAP1), a typical molecule of adherent junctions, has been found to be a tumor suppressor in many cancer types. Aberrant activation of β-catenin has been demonstrated to be associated with malignant biological properties of tumors including breast cancer. This study aimed to investigate the function and mechanism of AJAP1-mediated β-catenin activity of breast cancer lines in vitro and in breast cancer patients. Methods AJAP1 and β-catenin expressions in breast cancer tissues and cell lines were detected by immunohistochemistry, western blotting and qRT-PCR. The EGF/EGFR axis-mediated AJAP1 attenuated β-catenin nuclear location was measured by western blotting, immunofluorescence assay, co-immunoprecipitation, luciferase assay and ubiquitination assays. Furthermore, the function of AJAP1 and β-catenin regulated breast cancer progression was explored both in vivo and in vitro. Results It was found that AJAP1 had a high negative correlation with β-catenin nuclear expression and was a novel tumor suppressor in breast cancer. AJAP1 loss can mediate β-catenin accumulated in cytoplasm and then transferred it to the nucleus, activating β-catenin transcriptional activity and downstream genes. Additionally, β-catenin can reverse the invasion, proliferation ability and tumorigenicity of the depletion of AJAP1 caused both in vivo and in vitro. Besides, EGF/EGFR also involved in the process of AJAP1-depiction induced β-catenin transactivation to the nucleus. More importantly, EGFR depletion/AJAP1 knocked down promoted the progression of breast cancer by regulating the activity of β-catenin nuclear transactivation. Conclusion This study demonstrated that AJAP1 acted as a putative tumor suppressor while β-catenin nuclear localization positively fed back on EGF/EGFR-attenuated AJAP1 expression in breast cancer, which might be beneficial to develop new therapeutic targets for decreasing nuclear β-catenin-mediated malignancy in breast cancer.http://link.springer.com/article/10.1186/s13046-019-1252-6AJAP1β-CateninNuclear locationEGFEGFRTumor progression